Health Yuan In-Licenses Innovative Oral Small Molecule PREP Inhibitor from Bayer for COPD Treatment
Bayer
Pharmaceutical Product R&D Developer
▎WuXi AppTec Content Team Report
On March 22, Health Yuan announced that it has reached an agreement withBayerJust one itemSmall Molecule InhibitorExclusive License Agreement for Development, Commercialization, and Production in China Signed. According to the press release from HealthJoy, the product involved in this collaboration is one developed by Bayer.For Chronic Obstructive Pulmonary Disease (COPD)InnovativeOral Medication, has completed Phase 1 clinical trials in Europe.
COPD is a progressive disease that can cause airflow obstruction in the lungs, leading to weakened breathing."China Adult Pulmonary Health Study" shows that the number of COPD patients in China is about 100 million, with a prevalence rate of 8.6% among people over 20 years old, and up to 13.7% among those over 40 years old. COPD has ranked third among chronic non-communicable diseases. Currently, globally, regarding COPDOral MedicationThe choices are very limited, and clinical treatment mainly relies on bronchodilators, glucocorticoids, etc., with a lack of oral anti-inflammatory drug options.
The small molecule compounds involved in this cooperation of Health YuanBy inhibiting prolyl endopeptidase (PREP) activity, the production of COPD inflammatory mediators was effectively prevented.This unique mechanism of action is expected to benefit COPD patients and is also likely to have a positive impact on the overall progression of the disease.
According to the press release from Joincare, with the exclusive authorization obtained from Bayer this time, the company hasThree Important Strategic Partnerships Reached in the Respiratory Field. At the end of January 2024, Joincare announced in successionTwo Collaborations, respectivelyWith Quanxin Bio regardingTSLP AntibodyQX008N Reaches Strategic Cooperation with Boan BiotechAnti-IL-4Rα Long-Acting Monoclonal AntibodyBA2101 Injection Reaches Cooperation. Health Yuan PlansDevelopment of Two Drugs for the Treatment ofAsthma、COPDand other respiratory diseases. According to reports,The three collaborations, ranging from injectables to oral medications, further enrich Health Yuan's R&D pipeline and product portfolio in the respiratory field.
References:
[1] Health Yuan and Bayer Reach Exclusive Licensing Agreement for Small Molecule Inhibitor, Further Strengthening Innovative Drug Strategy and Expanding Pipeline in Respiratory Disease Area. Retrieved Mar 22, 2024, from https://mp.weixin.qq.com/s/QGVkkbCUPgl63sYKEeGpZg
This article was compiled and edited by the WuXi AppTec content team based on publicly available information. Individuals are welcome to share it on their social media feeds. For authorization to repost, please leave a message on the "MedView" WeChat Official Account to contact us. For other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.
